TELA Bio (TELA) Long-Term Deferred Tax (2019 - 2025)

TELA Bio's (TELA) quarterly Long-Term Deferred Tax came in at $62000.0 in Q3 2025, down 3.12% quarter-over-quarter from $64000.0 in Q2 2025.

TELA Bio (TELA) Long-Term Deferred Tax (2019 - 2025) Analysis & Trends

TELA Bio's Long-Term Deferred Tax history runs 3 years deep, the most recent figure standing at $62000.0 for Q3 2025.

On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $62000.0 in Q3 2025; TTM through Sep 2025 was $62000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $140000.0, changed N/A from the prior year.
Long-Term Deferred Tax slipped to $62000.0 in Q3 2025 per TELA's latest filing, from $64000.0 in the prior quarter.
Across five years, Long-Term Deferred Tax topped out at $140000.0 in Q4 2024 and bottomed at $62000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	TELA Bio	40.65 Mn	1.11 Mn	12.52 Mn

Download Data